Home » Topics » Disease categories and therapies » Gastrointestinal

Gastrointestinal
RSS

Merck and Isis researchers identify new HCV NS5B polymerase inhibitors

Sep. 18, 2002

MLN-02 fails to meet primary endpoint in phase II Crohn's disease trial

Sep. 17, 2002

Phase II Ceplene triple-drug trial cleared to continue

Sep. 17, 2002

Potential for Ono-AE1-329 in the treatment of inflammatory bowel disease

Sep. 17, 2002

Herbal complex safe and effective for the treatment of IBS

Sep. 13, 2002

GenOdyssee's interferon variants show preclinical potential in hepatitis C and cancer

Sep. 13, 2002

Small-molecule HCV NS3 protease inhibitors discovered at Boehringer Ingelheim

Sep. 12, 2002

Phase III alvimopan trial in opioid-induced bowel dysfunction completes enrollment

Sep. 12, 2002

Potent, orally active gastrin/CCK2 antagonists rationally designed at James Black Foundation

Sep. 5, 2002

Ferring describes SAR leading to low-molecular-weight hK1 inhibitors

Sep. 5, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...